These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36375125)

  • 1. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
    Olupot-Olupot P; Tomlinson G; Williams TN; Tshilolo L; Santos B; Smart LR; McElhinney K; Howard TA; Aygun B; Stuber SE; Lane A; Latham TS; Ware RE
    Blood; 2023 Mar; 141(12):1402-1410. PubMed ID: 36375125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
    McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
    Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Power-Hays A; Tomlinson GA; Tshilolo L; Santos B; Williams TN; Olupot-Olupot P; Smart LR; Aygun B; Lane A; Stuber SE; Latham T; Ware RE
    Am J Hematol; 2024 Apr; 99(4):625-632. PubMed ID: 38332651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
    McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
    Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
    Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa.
    Smart LR; Ambrose EE; Balyorugulu G; Songoro P; Shabani I; Komba P; Charles M; Howard TA; McElhinney KE; O'Hara SM; Odame J; Nakafeero M; Adams J; Stuber SE; Lane A; Latham TS; Makubi AN; Ware RE
    Acta Haematol; 2023; 146(2):95-105. PubMed ID: 35977532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monthly sulfadoxine/pyrimethamine-amodiaquine or dihydroartemisinin-piperaquine as malaria chemoprevention in young Kenyan children with sickle cell anemia: A randomized controlled trial.
    Taylor SM; Korwa S; Wu A; Green CL; Freedman B; Clapp S; Kirui JK; O'Meara WP; Njuguna FM
    PLoS Med; 2022 Oct; 19(10):e1004104. PubMed ID: 36215323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
    Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
    Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial.
    Ambrose EE; Latham TS; Songoro P; Charles M; Lane AC; Stuber SE; Makubi AN; Ware RE; Smart LR
    Lancet Haematol; 2023 Apr; 10(4):e261-e271. PubMed ID: 36870358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of current and emerging strategies for reducing morbidity from malaria in sickle cell disease.
    Aneni EC; Hamer DH; Gill CJ
    Trop Med Int Health; 2013 Mar; 18(3):313-27. PubMed ID: 23320577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
    Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
    Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blood count abnormalities in the association of sickle cell disease and malaria in clinical hematology at the CNHU-HKM in Cotonou (Bénin)].
    Zohoun AGC; Bagloagbodande T; Adanho A; Massi R; Houssou B; Orou Guiwa GG; Dèhoumon J; Mehou J; Anani L; Vovor A; Kindegazard D
    Med Trop Sante Int; 2024 Mar; 4(1):. PubMed ID: 38846115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
    Dexter D; McGann PT
    Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.
    Anyanwu JN; Williams O; Sautter CL; Kasirye P; Hume H; Opoka RO; Latham T; Ndugwa C; Ware RE; John CC
    JMIR Res Protoc; 2016 Jun; 5(2):e110. PubMed ID: 27339303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda.
    Namazzi R; Bond C; Conroy AL; Datta D; Tagoola A; Goings MJ; Jang JH; Ware RE; Opoka R; John CC
    Blood; 2024 Apr; 143(14):1425-1428. PubMed ID: 38169476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.